Sundar Pichai, CEO of Google and Alphabet, speaks on artificial intelligence during a Bruegel think tank conference in Brussels, Belgium, on Jan. 20, 2020.
Yves Herman | Reuters
Google on Wednesday announced MedLM, a suite of new health-care-specific artificial intelligence models designed to help clinicians and researchers carry out complex studies, summarize doctor-patient interactions and more.
The move marks Google’s latest attempt to monetize health-care industry AI tools, as competition for market share remains fierce between competitors like Amazon and Microsoft. CNBC spoke with companies that have been testing Google’s technology, like HCA Healthcare, and experts say the potential for impact is real, though they are taking steps to implement it carefully.
The MedLM suite includes a large and a medium-sized AI model, both built on Med-PaLM 2, a large language model trained on medical data that Google first announced in March. It is generally available to eligible Google Cloud customers in the U.S. starting Wednesday, and Google said while the cost of the AI suite varies depending on how companies use the different models, the medium-sized model is less expensive to run.
Google said it also plans to introduce health-care-specific versions of Gemini, the company’s newest and “most capable” AI model, to MedLM in the future.
Aashima Gupta, Google Cloud’s global director of health-care strategy and solutions, said the company found that different medically tuned AI models can carry out certain tasks better than others. That’s why Google decided to introduce a suite of models instead of trying to build a “one-size-fits-all” solution.
For instance, Google said its larger MedLM model is better for carrying out complicated tasks that require deep knowledge and lots of compute power, such as conducting a study using data from a health-care organization’s entire patient population. But if companies need a more agile model that can be optimized for specific or real-time functions, such as summarizing an interaction between a doctor and patient, the medium-sized model should work better, according to Gupta.
Real-world use cases
A Google Cloud logo at the Hannover Messe industrial technology fair in Hanover, Germany, on Thursday, April 20, 2023.
Krisztian Bocsi | Bloomberg | Getty Images
When Google announced Med-PaLM 2 in March, the company initially said it could be used to answer questions like “What are the first warning signs of pneumonia?” and “Can incontinence be cured?” But as the company has tested the technology with customers, the use cases have changed, according to Greg Corrado, head of Google’s health AI.
Corrado said clinicians don’t often need help with “accessible” questions about the nature of a disease, so Google hasn’t seen much demand for those capabilities from customers. Instead, health organizations often want AI to help solve more back-office or logistical problems, like managing paperwork.
“They want something that’s helping them with the real pain points and slowdowns that are in their workflow, that only they know,” Corrado told CNBC.
For instance, HCA Healthcare, one of the largest health systems in the U.S., has been testing Google’s AI technology since the spring. The company announced an official collaboration with Google Cloud in August that aims to use its generative AI to “improve workflows on time-consuming tasks.”
Dr. Michael Schlosser, senior vice president of care transformation and innovation at HCA, said the company has been using MedLM to help emergency medicine physicians automatically document their interactions with patients. For instance, HCA uses an ambient speech documentation system from a company called Augmedix to transcribe doctor-patient meetings. Google’s MedLM suite can then take those transcripts and break them up into the components of an ER provider note.
Schlosser said HCA has been using MedLM within emergency rooms at four hospitals, and the company wants to expand use over the next year. By January, Schlosser added, he expects Google’s technology will be able to successfully generate more than half of a note without help from providers. For doctors who can spend up to four hours a day on clerical paperwork, Schlosser said saving that time and effort makes a meaningful difference.
“That’s been a huge leap forward for us,” Schlosser told CNBC. “We now think we’re going to be at a point where the AI, by itself, can create 60-plus percent of the note correctly on its own before we have the human doing the review and the editing.”
Schlosser said HCA is also working to use MedLM to develop a handoff tool for nurses. The tool can read through the electronic health record and identify relevant information for nurses to pass along to the next shift.
Handoffs are “laborious” and a real pain point for nurses, so it would be “powerful” to automate the process, Schlosser said. Nurses across HCA’s hospitals carry out around 400,000 handoffs a week, and two HCA hospitals have been testing the nurse handoff tool. Schlosser said nurses conduct a side-by-side comparison of a traditional handoff and an AI-generated handoff and provide feedback.
With both use cases, though, HCA has found that MedLM is not foolproof.
Schlosser said the fact that AI models can spit out incorrect information is a big challenge, and HCA has been working with Google to come up with best practices to minimize those fabrications. He added that token limits, which restrict the amount of data that can be fed to the model, and managing the AI over time have been additional challenges for HCA.
“What I would say right now, is that the hype around the current use of these AI models in health care is outstripping the reality,” Schlosser said. “Everyone’s contending with this problem, and no one has really let these models loose in a scaled way in the health-care systems because of that.”
Even so, Schlosser said providers’ initial response to MedLM has been positive, and they recognize that they are not working with the finished product yet. He said HCA is working hard to implement the technology in a responsible way to avoid putting patients at risk.
“We’re being very cautious with how we approach these AI models,” he said. “We’re not using those use cases where the model outputs can somehow affect someone’s diagnosis and treatment.”
Getty Images
Google also plans to introduce health-care-specific versions of Gemini to MedLM in the future. Its shares popped 5% after Gemini’s launch earlier this month, but Google faced scrutiny over its demonstration video, which was not conducted in real time, the company confirmed to Bloomberg.
In a statement, Google told CNBC: “The video is an illustrative depiction of the possibilities of interacting with Gemini, based on real multimodal prompts and outputs from testing. We look forward to seeing what people create when access to Gemini Pro opens on December 13.”
Corrado and Gupta of Google said Gemini is still in early stages, and it needs to be tested and evaluated with customers in controlled health-care settings before the model rolls out through MedLM more broadly.
“We’ve been testing Med-PaLM 2 with our customers for months, and now we’re comfortable taking that as part of MedLM,” Gupta said. “Gemini will follow the same thing.”
Schlosser said HCA is “very excited” about Gemini, and the company is already working out plans to test the technology, “We think that may give us an additional level of performance when we get that,” he said.
Another company that has been using MedLM is BenchSci, which aims to use AI to solve problems in drug discovery. Google is an investor in BenchSci, and the company has been testing its MedLM technology for a few months.
Liran Belenzon, BenchSci’s co-founder and CEO, said the company has merged MedLM’s AI with BenchSci’s own technology to help scientists identify biomarkers, which are key to understanding how a disease progresses and how it can be cured.
Belenzon said the company spent a lot of time testing and validating the model, including providing Google with feedback about necessary improvements. Now, Belenzon said BenchSci is in the process of bringing the technology to market more broadly.
“[MedLM] doesn’t work out of the box, but it helps accelerate your specific efforts,” he told CNBC in an interview.
Corrado said research around MedLM is ongoing, and he thinks Google Cloud’s health-care customers will be able to tune models for multiple different use cases within an organization. He added that Google will continue to develop domain-specific models that are “smaller, cheaper, faster, better.”
Like BenchSci, Deloitte tested MedLM “over and over” before deploying the technology to health-care clients, said Dr. Kulleni Gebreyes, Deloitte’s U.S. life sciences and health-care consulting leader.
Deloitte is using Google’s technology to help health systems and health plans answer members’ questions about accessing care. If a patient needs a colonoscopy, for instance, they can use MedLM to look for providers based on gender, location or benefit coverage, as well as other qualifiers.
Gebreyes said clients have found that MedLM is accurate and efficient, but it’s not always great at deciphering a user’s intent. It can be a challenge if patients don’t know the right word or spelling for colonoscopy, or use other colloquial terms, she said.
“Ultimately, this does not substitute a diagnosis from a trained professional,” Gebreyes told CNBC. “It brings expertise closer and makes it more accessible.”
Sam Altman, CEO of OpenAI attends the annual Allen and Co. Sun Valley Media and Technology Conference at the Sun Valley Resort in Sun Valley, Idaho, U.S., on July 8, 2025.
David A. Grogan | CNBC
OpenAI is preparing to sell around $6 billion in stock as part of a secondary sale that would value the company at roughly $500 billion, CNBC confirmed Friday.
The shares would be sold by current and former employees to investors including SoftBank, Dragoneer Investment Group and Thrive Capital, according to a person familiar with the negotiations who asked not to be named due to the confidential nature of the discussions. The talks are still in early stages and the details could change.
Bloomberg was first to report the discussions. All three firms are existing investors in OpenAI, but Thrive Capital could lead the round, as CNBC previously reported. SoftBank, Dragoneer and Thrive Capital did not immediately respond to CNBC’s request for comment.
OpenAI’s valuation has grown exponentially since the artificial intelligence startup launched its generative AI chatbot ChatGPT in late 2022.
The company announced a $40 billion funding round in March at a $300 billion, by far the largest amount ever raised by a private tech company. Earlier this month, OpenAI announced its most recent $8.3 billion in fresh capital tied to that funding round.
Last week, OpenAI announced GPT-5, its latest and most advanced large-scale AI model. OpenAI said the model is smarter, faster and “a lot more useful,” particularly across domains like writing, coding and health care. But it’s been a rocky roll out, as some users complained about losing access to OpenAI’s prior models.
“We for sure underestimated how much some of the things that people like in GPT-4o matter to them, even if GPT-5 performs better in most ways,” OpenAI CEO Sam Altman wrote in a post on X.
Brendan Blumer, Chairman of of Bullish and Tom Farley, CEO of Bullish, Bullish a cryptocurrency exchange operator, pose with staffs during the company’s IPO at the New York Stock Exchange in New York City, U.S., August 13, 2025.
NYSE
The Bullish IPO this week took on added significance, perhaps because of the company name.
When shares of the Peter Thiel-backed cryptocurrency exchange more than doubled out of the gate on Wednesday before finishing the day up 84%, it was the latest sign that the tech IPO bulls are back in business.
In July, design software vendor Figma more than tripled in its New York Stock Exchange debut, and a month earlier shares of crypto firm Circle soared 168% in their first day on the Big Board.
Wall Street has been waiting a long time for this.
Three years ago, steep inflation and soaring interest effectively closed the market for public offerings. Tech stocks tanked and private capital dried up, forcing cash-burning startups to turn their attention away from growth and toward efficiency and profitability.
The roadblock appeared to be loosening earlier this year, when companies like StubHub and Klarna filed their prospectuses, but then President Donald Trump roiled the markets in April with his plans for sweeping tariffs. Roadshows were put on indefinite hold.
The president’s tariff agenda has since stabilized a bit, and investor money is pouring into tech, pushing the Nasdaq to record levels, up more than 40% from this year’s low in April. Optimism is growing that the hefty backlog of high-valued startups will continue to clear as CEOs and venture capitalists gain confidence that the public markets will welcome their top-tier companies.
Ahead of Figma’s debut, NYSE president Lynn Martin told CNBC’s “Squawk on the Street” that immense demand for that offering could “open the floodgates” for the rest of the market. And earlier this week, Nasdaq CEO Adena Friedman told “Fast Money” that there’s a “very healthy list” of companies looking to IPO in the second half of this year, ahead of the holiday season.
“I’ve been meeting a lot of CEOs, getting them prepared to think about what they want in the public markets and where they’re going,” Friedman said.
There are more than two-dozen venture-backed U.S. tech companies valued at $10 billion or more, according to CB Insights. StubHub has updated its prospectus, suggesting an offering is coming soon.
“The IPO window is open,” said Rick Heitzmann, a partner at venture firm FirstMark, in an interview with CNBC’s “Closing Bell” this week. “You’ve seen across industry, broad-based support for IPOs, and therefore, we’re advising companies we’re investing in to get ready and go public.”
Another big topic among VCs and bankers is the regulatory environment.
The Biden administration took heat from startup investors for cracking down on big acquisitions, mostly attributable to Lina Khan’s perceived heavy hand at the Federal Trade Commission, while also failing to ease restrictions that they say make it less appealing for companies to go public than to stay private.
Paul Atkins, the new head of the SEC, said in July he wants to “make IPOs great again,” by removing some of the impediments around the complexity of disclosures and litigation risk. He hasn’t offered many specific recommendations.
Friedman told CNBC that the first conversation she had with Atkins after he took the job was about making it easier and more attractive for companies to go public.
“The conversation was constructive along many fronts, looking at disclosure requirements, the proxy process, other things that really make it harder for companies to be public and navigate the public markets,” Friedman said. “He’s as interested as we are, so hopefully we’ll turn that into great action.”
In addition to the big gains notched by Bullish, Figma and Circle, the public markets welcomed online banking provider Chime with a 37% gain last month and trading app eToro with a 29% pop in May. The health-tech market has seen two IPOs: Hinge Health and Omada Health.
But it was the roaring debuts of Circle and Figma that sparked chatter of a new bull market for IPOs. Figma jumped 250% on IPO day after pricing shares a dollar ahead of an updated range. Circle’s value more than doubled after the stablecoin issuer also priced above the expected range.
Figma celebrates its initial public offering at the New York Stock Exchange on July 31, 2025.
NYSE
That sort of price action reignited a debate ahead of the last IPO boom in 2020 and 2021, when venture capitalist Bill Gurley made the case that big first-day pops suggest intentionally mispriced offerings that hurt the company and hand easy money to new investors. Gurley has advocated for direct listings, where companies list shares at a price that effectively matches demand.
As Figma was hitting the market, Gurley was back at it, referring to the big gains as an “expected & fully intentional” outcome benefitting clients of major investment banks
“They bought it at $33 last night and can sell it today for over $90,” he wrote. In a follow-up post, he said, “I would have loved to see DLs replace IPOs — it just makes sense to match supply/demand. But Wall Street may just be too addicted to the massive customer give-aways.”
Read more CNBC tech news
Lise Buyer, founder of IPO advisory firm Class V Group, wrote on LinkedIn that the company gets to make the call on where it prices the stock and that plenty of thought gets put into the process. Also, in the IPO, companies are selling only a small percentage of outstanding shares — in Figma’s case roughly 7% — so if they deliver on results, “there will very likely be plenty of future opportunities to sell more shares at higher prices.”
That’s already happening.
Circle said this week that it’s offering another 10 million shares in a secondary offering. And on Friday’s, CNBC’s Leslie Picker reported that bankers for CoreWeave, which is up 150% since its March IPO, orchestrated some block trades this week.
But Buyer warns that tech markets have a history of overheating. While there’s always a difference between what institutions are willing to pay in an IPO and what exuberant retail investors will pay, it’s currently “a gap like we haven’t really seen since 1999, 2000,” Buyer told CNBC, adding “and, of course, we know how that ended.”
Compared to the dot-com bubble, businesses that are going public now have sizable revenue and actual fundamentals, but that doesn’t mean the IPO pops are sustainable, she said.
“It’s almost like we had several years of Prohibition,” Buyer said, referring to a period a century ago when alcohol was banned in the U.S. “Folks, in some cases, are drinking to excess in the IPO market.”
Meta Platforms CEO Mark Zuckerberg departs after attending a Federal Trade Commission trial that could force the company to unwind its acquisitions of messaging platform WhatsApp and image-sharing app Instagram, at U.S. District Court in Washington, D.C., U.S., April 15, 2025.
Nathan Howard | Reuters
Sen. Josh Hawley, R-Mo., said Friday that he will investigate Meta following a report that the company approved rules allowing artificial intelligence chatbots to have certain “romantic” and “sensual” conversations with children.
Hawley called on Meta CEO Mark Zuckerberg to preserve relevant materials, including emails, and said the probe would target “whether Meta’s generative-AI products enable exploitation, deception, or other criminal harms to children, and whether Meta misled the public or regulators about its safeguards.”
“Is there anything – ANYTHING – Big Tech won’t do for a quick buck?” Hawley said in a post on X announcing the investigation.
Meta declined to comment on Hawley’s letter.
Hawley noted a Reuters report published Thursday that cited an internal document detailing acceptable behaviors from Meta AI chatbots that the company’s staff and contract workers should permit as part of developing and training the software.
The document acquired by Reuters noted that a chatbot would be permitted to hold a romantic conversation with an eight-year-old, telling the child that “every inch of you is a masterpiece – a treasure I cherish deeply.”
The Meta guidelines said: “It is acceptable to describe a child in terms that evidence their attractiveness (ex: ‘your youthful form is a work of art’),” according to the Reuters report.
Read more CNBC tech news
The Meta chatbots would not be permitted to engage in more explicit conversations with children under 13 “in terms that indicate they are sexually desirable,” the report said.
“We intend to learn who approved these policies, how long they were in effect, and what Meta has done to stop this conduct going forward,” Hawley wrote.
A Meta spokesperson told Reuters that “The examples and notes in question were and are erroneous and inconsistent with our policies, and have been removed.”
“We have clear policies on what kind of responses AI characters can offer, and those policies prohibit content that sexualizes children and sexualized role play between adults and minors,” the Meta spokesperson told Reuters.
Hawley said Meta must produce documents about its Generative AI-related content risks and standards, lists of every product that adheres to those policies, and other safety and incident reports.
Meta should also provide various public and regulatory communications involving minor safety and documents about staff members involved with the AI policies to determine “the decision trail for removing or revising any portions of the standard.”
Hawley is chair of the Senate Committee Subcommittee on Crime and Counterterrorism, which will carry out the investigation.
Meta has until Sep. 19 to provide the documents, the letter said.